Encyclopedia entry
Sermorelin
Sermorelin is a 29-amino-acid GHRH analogue. FDA-approved between 1990 and 2008 as Geref for paediatric growth hormone deficiency. The original approval was withdrawn in 2008 for commercial reasons rather than safety. Sermorelin has therefore moved out of the licensed-medicine tier and into the research-chemical and compounding-pharmacy markets.
Pharmaceutical history
- · Developed by Serono (now Merck Serono).
- · FDA-approved 1990 for paediatric growth hormone deficiency, brand name Geref.
- · FDA approval withdrawn 2008 (commercial, not safety-driven).
- · Returned to off-label and compounded use in the US through anti-aging and longevity clinics.
- · No UK marketing authorisation. Not stocked by NHS pharmacies.
UK regulatory status
- · No UK marketing authorisation, currently.
- · Sold by UK research-peptide retailers under "research use only" framing.
- · On the WADA prohibited list (S2 peptide hormones).
Where to learn more
- · FDA approval and withdrawal documentation, archived.
- · Compounded sermorelin literature in US anti-aging journals (note: methodological caveats).
- · UK retailer comparison: research peptides UK retailers.
Popular on PeptideClear
Ready to buy
Buy SERMORELIN in the UK
UK retailers compared by price, Trust Index, and CoA practice. Editorial commentary only. Research use only.